Assessment and characterization of the cytolytic T lymphocyte response against Epstein-Barr virus in patients with non-Hodgkin's lymphoma after autologous peripheral blood stem cell transplantation

Bone Marrow Transplantation

Volumn 21, Issue 9, 1998, Pages 909-916

  Nolte, A ^a,b   Buhmann, R ^a,b   Straka, C ^b   Emmerich, B ^b   Hallek, M ^a,b  

^a UNIVERSITY OF MUNICH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Autologous PBSCT; Cellular immune response; CTL response; Epstein Barr virus

Indexed keywords

CD56 ANTIGEN; HLA A ANTIGEN; HLA B ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD3; OKT 8;

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CELL STIMULATION; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; EPSTEIN BARR VIRUS; FEMALE; HAPLOTYPE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; LYMPHOBLASTOID CELL LINE; LYMPHOCYTE PROLIFERATION; MALE; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; VIRUS INFECTION;

EID: 0031919739     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701197     Document Type: Article

References (35)

1. Schmitz N. Rezidivtherapie hochmaligner Non-Hodgkin-Lymphome. Internist 1997; 38: 143-149.
2. Schmitz N, Linch DC, Dreger P et al. Randomised trial of filgastrim-mobilized peripheral blood progenitor cell transplantation versus autologous bone marrow transplantation in lymphoma patients. Lancet 1996; 347: 353-357.
3. To LB, Roberts MM, Haylock DN et al. Comparison of hematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants. Bone Marrow Transplant 1992; 9: 277-284.
4. Chao NH, Schriber JR, Grimes K et al. Granulocyte colony-stimulating factor 'mobilized' peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy. Blood 1993; 81: 2031-2035.
5. Vose JM, Anderson JR, Kessinger A et al. High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma. J Clin Oncol 1993; 11: 1846-1851.
6. Fegan C, Thomas H, Bailey-Wood R et al. In vitro LAK (lymphokine activated killer) activity following autologous peripheral blood stem cell is significantly greater than that following autologous bone marrow and allogeneic bone marrow transplantation. Bone Marrow Transplant 1995; 16: 277-281.
7. Guillaume T, Sekhavat M, Rubinstein DB et al. Defective cytokine production following autologous transplantation for solid tumors and hematologic malignancies regardless of bone marrow or peripheral origin and lack of evidence for a role for interleukin-10 in delayed immune reconstitution. Cancer Res 1994; 54: 3800-3807.
8. Kiesel S, Pezzutto A, Körbling M et al. Autologous peripheral blood stem cell transplantation: analysis of autografted cells and lymphocyte recovery. Transplant Proc 1989; 21: 3084-3088.
9. Roberts MM, To LB, Gillis D et al. Immune reconstitution following peripheral blood stem cell transplantation, autologous bone marrow transplantation and allogeneic bone marrow transplantation. Bone Marrow Transplant 1993; 12: 469-475.
10. Scheid C, Pettengell R, Ghielmini M et al. Time-course of the recovery of cellular immune function after high-dose chemotherapy and peripheral blood progenitor cell transplantation for high-grade non-Hodgkin's lymphoma. Bone Marrow Transplant 1995; 15: 901-906.
11. Rickinson AB, Moss DJ, Wallace LE et al. Long-term T-cell-mediated immunity to Epstein-Barr virus. Cancer Res 1981; 41: 4216-4221.
12. Bourgault I, Gomez A, Gomard E et al. Limiting-dilution analysis of the HLA restriction of anti-Epstein-Barr virus-specific cytolytic T lymphocytes. Clin Exp Immunol 1991; 84: 501-507.
13. Moss DJ, Wallace LE, Rickinson AB et al. Cytotoxic T cell recognition of Epstein-Barr virus-infected B-cells: I. Specificity and HLA-restriction of effector cells reactivated in vitro. Eur J Immunol 1981; 11: 686-693.
14. Murray RJ, Kurilla MG, Brooks JM et al. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies. J Exp Med 1992; 176: 157-168.
15. Khanna R, Burrows S, Kurilla M et al. Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development. J Exp Med 1992; 176: 169-176.
16. Gavioli R, Kurilla MG, Campos-Lima de PO et al. Multiple HLA A11-restricted cytotoxic T-lymphocyte epitopes of different immunogenicities in the Epstein-Barr virus-encoded nuclear antigen 4. J Virol 1993; 67: 1572-1578.
17. Burrows SR, Gardner J, Khanna R et al. Five new cytotoxic T cell epitopes identified within Epstein-Barr virus nuclear antigen 3. J Gen Virol 1994; 75: 1-5.
18. Crawford DH, Edwards JBM, Sweny P et al. Long-term T-cell-mediated immunity to Epstein-Barr virus in renal-allograft recipients receiving cyclosporin A. Lancet 1981; 1: 10-18.
19. Zutter MM, Martin PJ, Sale GE et al. Epstein-Barr virus lymphoproliferation after bone marrow transplantation. Blood 1988; 72: 520-529.
20. Papadopoulos EB, Ladanyi M, Emanuel D et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. New Engl J Med 1994; 330: 1185-1191.
21. Heslop HE, Brenner MK, Rooney CM. Donor T cells to treat EBV-associated lymphoma. New Engl J Med 1994; 331: 679-680.
22. Straka C, Drexler E, Mitterer M et al. Autotransplantation of B-cell purged peripheral blood progenitor cells in B-cell lymphoma. Lancet 1995; 345: 797-798.
23. Mitterer M, Hirber J, Gentilini I et al. Target value tailored (TVT) apheresis approach for blood progenitor cell collection after high-dose chemotherapy and rh-G-CSF. Bone Marrow Transplant 1996; 18: 611-617.
24. Adler S, Langenmayer I, Kaspar M et al. High-dose busulfan and cyclophosphamide with autologous peripheral blood progenitor cell transplantation in patients with relapsed lymphoma - efficacy and toxicity. Ann Oncol 1996; 7 (Suppl. 3): 177.
25. Rabin J, Hopkins RF, Ruscetti FW et al. Spontaneous release of a factor with properties of T cell growth factor from a continuous line of primate tumour cells. J Immunol 1981; 127: 1852-1856.
26. Crawford DH. Mulholland N, Iliescu V et al. Epstein-Barr virus infection and immunity in bone marrow transplant recipients. Transplantation 1986; 42: 50-54.
27. Verma UN, Areman E, Dickerson SA et al. Interleukin-2 activation of chemotherapy and growth factor-mobilized peripheral blood stern cells for generation of cytotoxic effectors. Bone Marrow Transplant 1995; 15: 199-206.
28. Scambia G, Panici PB. Pierelli L et al. Immunological reconstitution after high-dose chemotherapy and autologous blood stem cell transplantation for advanced ovarian cancer. Eur J Cancer 1993; 29a: 1518-1522.
29. Lucas KG, Small TN, Heller G et al. The development of cellular immunity to Epstein-Barr virus after allogeneic bone marrow transplantation. Blood 1996; 87:2594-2603.
30. Velardi A, Varese P, Grossi EE et al. Cytolytic function of clonable T cells after human bone marrow transplantation. Blood 1990; 75: 1364-1369.
31. Rozans MK, Smith BR, Burakoff SJ et al. Long-lasting deficit of functional T cell precursors in human bone marrow transplant recipients revealed by limiting dilution methods. J Immunol 1986; 136: 4040-4048.
32. Daley JP, Rozans MK, Smith BR et al. Retarded recovery of functional T cell frequencies in T cell-depleted bone marrow transplant recipients. Blood 1987; 70: 960-964.
33. Charmot D, Ragueneau M, Olive D et al. Generation of CD8 cytolytic T cells early after autologous or allogeneic bone marrow transplantation. Bone Marrow Transplant 1987; 2: 183-194.
34. Tilkin AF, Bagot M, Dreyfus F et al. Reconstitution of cytolytic T lymphocyte activity following allogeneic bone marrow transplantation in man. Transplantation 1987; 44: 303-308.
35. Duncombe AS, Grundy JE, Oblakowski P et al. Bone marrow transplant recipients have defective MHC-unrestricted cytotoxic responses against cytomegalovirus in comparison with Epstein-Barr virus: the importance of target cell expression of lymphocyte function-associated antigen 1 (LFA1). Blood 1992; 79: 3059-3066.